This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts' Actions: JNJ FNFG WLL CA VRTX

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

CA (CA - Get Report) was downgraded from buy to neutral at Mizuho. $25 price target. CEO could change the product development process, which might cause near-term disruptions, Mizuho said.

F5 Networks (FFIV) was downgraded to hold at TheStreet Ratings.

First Niagara (FNFG - Get Report) was upgraded to outperform at KBW. $10.50 price target. New CEO could prove to be an inflection point for the company, Keefe, Bruyette & Woods said.

Johnson & Johnson (JNJ - Get Report) was downgraded to neutral from overweight at J.P. Morgan. $83 price target. Valuation call.

Juniper Networks (JNPR) was upgraded at Argus to buy from hold. $22 price target. Earnings recovery is finally underway, Argus said.


L-3 Communications (LLL) was downgraded at J.P. Morgan to underweight from neutral. Company is most at risk from sequestration cuts, J.P. Morgan said.

Vail Resorts (MTN) was downgraded at Credit Suisse to neutral from outperform. $64 price target. Valuation call, as the stock is up 44% over the past year, Credit Suisse said.

Northrop Grumman (NOC) was upgraded at J.P. Morgan to equal-weight from underweight. Valuation call, J.P. Morgan said.

Public Service (PEG) was downgraded at Argus to hold from buy. Valuation call, as the stock is approaching the previous $35 price target, Argus said.


RDA Microelectronics (RDA) was downgraded to hold at TheStreet Ratings.

Vertex Pharmaceuticals (VRTX - Get Report) was initiated with a hold rating at Canaccord. Valuation call, based on a $55 price target.

Whiting Petroleum (WLL - Get Report) was upgraded to overweight at J.P. Morgan. Valuation call, given the company's better outlook, J.P. Morgan said.

STOCK COMMENTS/EPS CHANGES

Apple (AAPL) estimates were increased at Canaccord Genuity through 2014. Company is seeing higher iPhone 4 and 4S sales, and new products should continue to drive demand. Buy rating and $600 price target.

AstraZeneca (AZN) estimates were cut at Leerink Swann through 2014. Cautious feedback for Fostamatinib lowers the chance for FDA approval, Leerink Swann said.

Daimler (DDAIF) price target and estimates were reduced at UBS. First-quarter guidance was worse than expected on weak markets (Germany) and wholesale sales, driving a reduction in earnings estimates, said UBS. The price target goes to $70.22.

Hanesbrands (HBI) price target and estimates were increased at Citigroup. The price target was increased to $54 after the company initiated a dividend which will attract new investors, said Citigroup. Earnings estimates for 2013 were increased given a better-than-expected first quarter result, Citigroup added.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
CA $31.40 -1.24%
FNFG $8.93 -1.22%
JNJ $99.50 -0.85%
WLL $36.84 -2.92%
VRTX $122.15 -3.29%

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs